Participant flow

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis · Source last updated 2013-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Lenalidomide (Len) 15mg daily (days 1-21) Cyclophosphamide (Cyc) 300 mg/m\^2 (days 1, 8, 15) Dexamethasone (Dex) 40 mg weekly

   id

   FG000

   title

   Len/Cyc/Dex

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         12

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Alternative treatment

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Disease progression

   5. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Other, not specified

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         35

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         29

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Thirty-five(35) participants were recruited between December 2007 and November 2008 at Mayo Clinic.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice